Tenaya Therapeutics
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
171 Oyster Point Blvd Ste 500, South San...Phone Number
(650) 825-6990Website
www.tenayatherapeutics.comRevenue
<$5 MillionStock Symbol
TNYAIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company focused on developing gene therapies and precision medicines for genetic heart diseases. The company leverages human genetics, viral vector engineering, and cellular models to design potentially curative treatments for cardiomyopathies such as hypertrophic and arrhythmogenic cardiomyopathy, aiming to address the underlying causes of heart failure.Explore more
Tenaya Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tenaya Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Tenaya Therapeutics recently announced quarterly report
Check out if Tenaya Therapeutics is spiking on competitors!
Tenaya Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Tenaya Therapeutics launches new products
Click to see if Tenaya Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Tenaya Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Tenaya Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Tenaya Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined Tenaya Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Tenaya Therapeutics
Compare insights from companies similar to Tenaya Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tenaya Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Tenaya Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Tenaya Therapeutics.
Tenaya Therapeutics financials insights
Gather financial insights about Tenaya Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$50M
2019
Series B
$92M
2021
Series C
$106M
Share Placement
$180M
Tenaya Therapeutics Tech Stack
A closer look at the technologies used by Tenaya Therapeutics
See more technologies
Most Recent Scoops
Person-Based
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Scott Bertch, Vice President, Clinical Manufacturing Site Head, has recently left the organization and now serves as Chief Operating Officer for cGMPnow.
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Project
Tenaya Therapeutics News & Media
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease CharacteristicsTenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that members of management will host 1x1 meetings with investors at the upcoming Canaccord Genuity 46th Annual Growth Conference taking place from August 11-12, 2026 in Boston, Massachusetts. Eric Hyllengren,Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to tTenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tenaya Therapeutics
Sign Up For FreeTo access detailed company insights
Tenaya Therapeutics is a clinical-stage biotechnology company focused on developing gene therapies and precision medicines for genetic heart diseases. The company leverages human genetics, viral vector engineering, and cellular models to design potentially curative treatments for cardiomyopathies such as hypertrophic and arrhythmogenic cardiomyopat... Read More
